Weight regain after stopping tirzepatide: SURMOUNT-4 data and the 5-year cost math
Two-thirds of weight lost comes back within a year of stopping. Here's the SURMOUNT-4 data, the decade-level cost of staying on treatment, and why the pricing model you pick at month one matters for years.
SURMOUNT-4: what happens when you stop
SURMOUNT-4 had an important design: patients received tirzepatide for 36 weeks (average loss ~21%), then were randomized to continue tirzepatide or switch to placebo for 52 more weeks. The continued-treatment group maintained their loss and added an additional ~6%, reaching ~26% from baseline. The switched-to-placebo group regained about two-thirds of what they'd lost — ending about 10% below their original weight. That 10% residual is not nothing, but it's a far cry from the clinical benefit of maintained treatment.
| SURMOUNT-4 group | Wk 36 (end of open-label) | Wk 88 (end of double-blind) | Net change Wk 36→88 |
|---|---|---|---|
| Continue tirzepatide | −21.1% | −26.0% | −4.9% (continued loss) |
| Switch to placebo | −21.1% | −9.8% | +11.3% (regain) |
The maintenance economics
Chronic treatment has chronic costs. The question isn't whether you spend $186/month for one year — it's whether you spend it for five years, or ten. Flat-rate compounded at $186/month totals $11,160 over five years and $22,320 over ten. At brand retail it's $70,500 and $141,000 respectively. This is the frame that makes the pricing model you choose at month one consequential for the long run.
Options for long-term management
The literature and clinical practice both point toward tirzepatide as indefinite therapy for most patients who respond — similar to how antihypertensives or statins are managed. That reframes the cost question: you're not evaluating a one-year drug, you're evaluating a maintenance medication, possibly for decades. Options worth discussing with a prescriber: maintenance at a lower dose (SURMOUNT-4's continued group included some dose adjustment), structured exercise and dietary support, and regular reassessment of whether the medication is producing sufficient benefit to justify continued cost. None of these are reasons to stop without a prescriber's guidance — they are conversation starters.
The decision framework: price the decade, not the month
The single most useful reframe in tirzepatide purchasing is to think in years, not months. A $186/month flat-rate plan that doesn't escalate saves roughly $2,900/year versus a dose-tiered trajectory — that's $14,500 over five years, $29,000 over ten. That difference buys a lot of visits, labs, and flexibility. It's also why our rubric weights pricing predictability at 25 points out of 100, and why NexLife's flat-rate-for-the-treatment-lifetime model earns its score. As always, whether treatment should continue is a clinical decision, not a financial one.
Frequently asked questions
What is SURMOUNT-4?
SURMOUNT-4 randomized patients who had lost ~21% body weight after 36 weeks of tirzepatide to continue treatment or switch to placebo for 52 more weeks. Continued treatment produced an additional ~5% loss (reaching ~26% from baseline); the switch group regained about two-thirds of their initial loss, ending ~10% below baseline.
How much weight do you regain after stopping tirzepatide?
In SURMOUNT-4, patients who stopped tirzepatide regained about 11 percentage points of the 21% they'd lost — ending roughly 10% below their original weight at one year. Most of the regain occurred in the first 6 months after stopping.
Is tirzepatide a lifetime medication?
For most patients who respond, the clinical framing is increasingly similar to other chronic-disease medications: the benefit is present while taking it and largely reverses when you stop. Individual management — including duration, dose, and lifestyle support — is a clinical decision for your prescriber.
How much does long-term tirzepatide cost over 5 years?
At July 2026 prices: flat-rate compounded ($186/mo) totals ~$11,160 over five years; a dose-tiered trajectory totals ~$25,700; brand retail totals ~$70,500. These figures assume stable advertised prices, which will change.
References
- Aronne LJ, et al. SURMOUNT-4 — continued tirzepatide vs placebo after weight loss. JAMA. 2024.
- Jastreboff AM, et al. SURMOUNT-1 primary results. N Engl J Med. 2022.
- TirzepatidePriceGuide.com July 2026 price report and price-trends page.
- Eli Lilly. Zepbound Prescribing Information.
Clinical data from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026. Not medical or financial advice.